KEKojo Elenitoba-Johnson

Kojo Elenitoba-Johnson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kojo Elenitoba-Johnson has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Quantitative reverse transcription PCR coupled with high-resolution melting for simultaneous detection and quantification of four isoforms of BCR::ABL1

    by Ting Zhou, Ayman Mohamed, Ben L Legendre, Heather Newell, Kojo S J Elenitoba-Johnson

    Aims: The diagnosis and therapeutic decision-making in chronic myeloid leukaemia (CML) depend on the detection and quantification of BCR::ABL1 . Currently, no clinical assay is used in routine practice to simultaneously quantify multiple BCR::ABL1 isoforms, requiring separate tests for each isoform. To address this challenge, we have developed and optimised an assay (BloodHound) that leverages quantitative reverse transcription PCR (RT-qPCR) and high-resolution melting (HRM) technologies to simultaneously detect and quantify four BCR::ABL1 isoforms (p190, p210, p230 and p203), with a limit of detection of 0.001%. Methods: To evaluate the clinical utility of this assay, we analysed 895 peripheral blood and bone marrow samples from patients with suspected, established or relapsed CML. Sanger sequencing was used as an orthogonal method to confirm fusion junction identity, and the Qiagen ipsogen BCR::ABL1 RT-qPCR assay was used for quantitative comparison. Results: BCR::ABL1 was detected in 20.9% of samples, with p210 alone being the most prevalent (86.1% (161/187), 95 CI 80.3% to 90.7%), followed by coexpression of p190 and p210 (12.3% (23/187), 95% CI 7.6% to 17.0%), while p190 alone (1.1% (2/187), 95% CI 0.1% to 3.8%) and p230 alone (0.5% (1/187), 95% CI 0% to 2.9%) were rare and p203 was not detected. The assay demonstrated high sensitivity and specificity, with 100% concordance with Sanger sequencing and showed excellent agreement with the Qiagen BCR::ABL1 RT-qPCR assay (r=0.998). Conclusions: The present multiplex RT-qPCR/HRM assay may help streamline clinical workflows, enhance diagnostic precision and offer a practical platform for studying CML clonal dynamics. It also holds promise for facilitating interlaboratory standardisation of non-p210 quantification.

  • Open Access

    Quality Management System in Clinical Digital Pathology Operations at a Tertiary Cancer Center

    by Orly Ardon, Marc Labasin, Maria Friedlander, Allyne Manzo, Lorraine Corsale, Peter Ntiamoah, Jeninne Wright, Kojo Elenitoba-Johnson, Victor E. Reuter, Meera R. Hameed, et al.


  • Open Access

    Digital pathology operations at a tertiary cancer center: Infrastructure requirements and operational cost

    by Orly Ardon, Eric Klein, Allyne Manzo, Lorraine Corsale, Christine England, Allix Mazzella, Luke Geneslaw, John Philip, Peter Ntiamoah, Jeninne Wright, et al.


  • Open Access

    High-resolution melting assay for rapid, simultaneous detection of JAK2, MPL and CALR variants

    by Christopher M Sande, Guang Yang, Ayman Mohamed, Ben L Legendre, Danielle Pion, Stephanie L Ferro, Kate Grimm, Kojo S J Elenitoba-Johnson

    Aims: Identification of recurrent genetic alterations in JAK2, MPL and CALR remains crucial in the diagnosis of Philadelphia-negative myeloproliferative neoplasms (MPNs). Current laboratory testing algorithms may entail batching and/or sequential testing, involving multiple testing modalities and sometimes send-out testing that increase the technical and economic demands on laboratories while delaying patient diagnoses. To address this gap, an assay based on PCR and high-resolution melting (HRM) analysis was developed for simultaneous evaluation of JAK2 exons 12–14, MPL exon 10 and CALR exon 9, embodied in the HemeScreen® (hereafter ‘HemeScreen’) MPN assay. Methods: The HemeScreen MPN assay was validated with blood and bone marrow samples from 982 patients with clinical suspicion for MPN. The HRM assay and Sanger sequencing were performed in independent Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories with Sanger sequencing (supported by droplet digital PCR) serving as the gold standard. Results: HRM and Sanger sequencing had an overall concordance of 99.4% with HRM detecting 133/139 (96%) variants confirmed by sequencing (9/10 MPL, 25/25 CALR, 99/104 JAK2), including 114 single nucleotide variants and 25 indels (3–52 bp). Variants consisted of disease-associated (DA) variants (89%), variants of unclear significance (2%) and non-DA variants (9%) with a positive predictive value of 92.3% and negative predictive value of 99.5%. Conclusions: These studies demonstrate the exquisite accuracy, sensitivity and specificity of the HRM-based HemeScreen MPN assay, which serves as a powerful, clinically applicable platform for rapid, simultaneous detection of clinically relevant, somatic disease variants.


  • Rapid and Automated Semiconductor-Based Next-Generation Sequencing for Simultaneous Detection of Somatic DNA and RNA Aberrations in Myeloid Neoplasms

    by Christopher M. Sande, Rui Wu, Guang Yang, Robyn T. Sussman, Ashkan Bigdeli, Chase Rushton, Akshay Chitturi, Jay Patel, Philippe Szankasi, Jennifer J.D. Morrissette, et al.